Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fallopian Tube Neoplasms”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,261 records · Page 70Linked to original sources
PubMed2000

[Adnexal masses in the Surgical Clinic of the University Hospital Center of Dakar, 74 cases].

The aim of this study was to assesss epidemiological, clinical and the therapeutic aspects of annexial masses. We have performed a retrospective study from 15/09/1994 up to 31/12/1997 including 74 patients. The prevalence rate was 18.40% of the overall gynecologic surgery in our department. Mean age was 36 years old. The range 30-41 years represented 40.5% of our cases. The mean gestity was 4 and the average parity 4. The most common clinical features were pelvic pains (75.57%) and hypogastric masses (50%). The duration of the disease ranged from 1 to 10 years. The general status was good in 94.59% of cases, bad with ascites in 5.41%. The annexial masses were cystic in 87.83%. The ovarian cysts were located at the both sides in 45.94, and bilateral in 8.10%. The annexial masses were solid in 9.45%. An abscess was found in 6.75%. We have performed an annexectomy in 66.1% and a cystectomy in 16.21%. The post operative complications were wound suppuration in 13.51%. The mortality rate was 1.35%. At the long-term follow up we have noticed an eventration in 1.35% and a recurrence with need of reintervention in 16.21%. The pathologic exam found a benign tumor in 95.16% and a carcinoma in 4.84%. The annexial masses are very common in our practice. They involve young multipare women. The main clinical outcome is pelvic pains. Annexectomy is the principal treatment.

Academic Medical Centers↗
PubMed1992

Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?

Despite showing high objective response rates (70% to 80%) to cisplatin- or carboplatin-based chemotherapy, most patients with ovarian cancer ultimately die of complications of their disease. Etoposide, given either as a single agent or in combination with the organoplatinum compounds, has produced disappointingly low response rates in the salvage setting. Based on recent data that suggest chronic administration of oral etoposide is superior to single daily dosing every 3 to 4 weeks, and the failure of previous trials to evaluate etoposide's activity in cisplatin-resistant malignancies, we have begun a phase II trial of chronic, low-dose oral etoposide in patients with clinically defined, platinum-resistant ovarian cancer. Thus far, 11 patients have been entered into the study. Neutropenia, the most prevalent toxicity, has precluded several patients from receiving the full 20-day course of 50 mg/d. No responses to treatment have been observed in nine evaluable patients. The study continues to accrue patients. The final results of this study and other trials should help determine the efficacy of chronic low-dose oral etoposide administration in patients with ovarian cancer.

Administration, Oral↗
PubMed2004

[Diagnostic value of laparoscopy for pelvic masses in perimenopausal and postmenopausal women].

OBJECTIVE: To evaluate the value of laparoscopy in the diagnosis of pelvic masses in perimenopausal and postmenopausal women. METHODS: The results of laparoscopic examination performed in 117 perimenopausal and postmenopausal women with pelvic masses were retrospectively analyzed. RESULTS: Malignant tumors in 19 cases (16.2%) and benign tumors were identified in 98 cases, and all of them managed laparoscopically. CONCLUSION: Laparoscopy is safe and accurate in diagnosing pelvic masses in perimenopausal and postmenopausal women, and may help define the quality of the masse and provides means for early detection and treatment of malignant tumors.

Adult↗
PubMed2004

Microscopic endometrioid carcinoma arising in endosalpingeal endometriosis.

We present a case of microscopic adenocarcinoma arising in the right fallopian tube, which was incidentally found in 74-year-old woman undergoing total abdominal hysterectomy with salpingo-oophorectomy for uterine myoma, hematometra and bilateral hydrosalpinx. A small focus of endometrioid adenocarcinoma confined within the endosalpingeal mucosa of the right fallopian tube associated with endometriosis was fortuitously found during histological examination. Our case seems to be unique since it shows an evident filiation between the lesions of tubal endometriosis and an adjoining focus of microscopic carcinoma. This is the second case report of a microscopic endometrioid carcinoma associated with endosalpingeal endometriosis.

Aged↗
PubMed2004

[Primitive adenocarcinoma of the fallopian tube: a case report].

Tubal carcinoma is rare and its prognosis is poor. His diagnosis before intervention is not easy because clinic is poor and complementary exams not specifics. His treatment is radical surgery by laparoscopy associated with chemotherapy. The prognosis is correlated with cancer stage and residual tumoral volume after surgery. We report a 55 years case who underwent coelioscpic annexectomy for left pyosalpinx. Definitive histology answered tubal cancer. Patient dead after three months because disseminated and parietal metastasis.

Adenocarcinoma↗
PubMed2004

Primary fallopian tube cancer--a ten year review. Clinicopathological study of 12 cases.

Primary fallopian tube cancer is the rarest of all gynecologic cancers, presenting as benign pelvic disease or more often as ovarian cancer and almost all cases are diagnosed at operation or autopsy. Primary adenocarcinoma is the most common histological type of primary tube cancer which has traditionally been managed and treated in the same manner as epithelial ovarian cancer. However, unlike ovarian cancer, fallopian tube cancer is not routinely suspected and treatment may be delayed and also seems to have a worst prognosis than ovarian cancer. We present a retrospective study involving 12 patients with primary fallopian tube cancer treated in our department. The clinicopathologic characteristics and treatment are reviewed.

Adenocarcinoma↗
PubMed1992

[Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors].

At our clinic for peritoneal dissemination cases of gynecological malignant tumors, we have been using intraperitoneal administration (ip) of anticancer agents such as CDDP with favorable results. However, since CDDP cannot be used for patients with renal dysfunction, we have administered CBDCA ip, and along with determining drug concentration, we also studied therapeutic effects. At the time of laparotomy in 5 cases of malignant tumors (ovarian cancer 4 cases, oviduct cancer 1 case), we subcutaneously implanted a reservoir port for the peritoneum in the upper inguinal region. Through this completely open port we administered by natural dripping 200-450 mg/body of CBDCA dissolved abdominal fluid and peripheral venous blood, and we determined the concentrations of total and free platinum. The ip concentration of platinum reached a peak of 142-19.8 micrograms/ml immediately after administration, and then gradually declined; at 8 hours it became 20.1-2.23 micrograms/ml, and was still detectable at 48 hours. In the peripheral venous blood peaked at 2 hours at 4.78-1.2 micrograms/ml, and was still observed at 48 hours. One 84-year-old patient with stage III oviduct cancer and renal dysfunction showed a marked reduction in ascites and improvement in PS from 4 to 1, so she is being treated on an outpatient basis. The efficacy rate was 60.0% with 2 CR and 1PR. Repeated ip administration of CBDCA was possible even in cases with renal damage rather than CDDP, but the side effects on the blood were severe. CBDCA ip achieves an effective level of free platinum in both the peritoneum administration methods for treating peritoneal disseminated cases.

Administration, Oral↗
PubMed2004

[Combination chemotherapy with docetaxel+carboplatin in the treatment of cancer of the ovary and fallopian tube].

Docetaxel and carboplatin were used as adjuvant chemotherapy or maintenance chemotherapy for cancer of the ovary and fallopian tube. Docetaxel 70 mg/m2 and carboplatin (area under the concentration-versus-time curve of 5) were administered intravenously every 3 weeks. Thirty-two patients (median age, 54 years) were assessable. We had objective responses from 5 of 7 (70%) assessable patients. Our toxicity findings included the following: grade 3 or 4 neutropenia (70% of courses); grade 3 or 4 leucocytopenia (35% of courses); hypersensitive reaction (25% of patients, none requiring discontinuation of therapy): edema (30% of patients): peripheral neuropathy (6% of patients). The combination of docetaxel and carboplatin is highly active in cancer of the ovary and follapian tube. The adverse effect was significant neutropenia, but peripheral neuropathy was rare. This regimen represents a reasonable first-line option for patients with ovarian cancer.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[Primary cancer of the fallopian tube. A case revealed by pelvic peritonitis].

We report the case of a primary carcinoma of the fallopian tube in which the diagnosis was done through laparoscopy for pelvic peritonitis. The pathologic diagnosis was possible with tubal sampling at the same time. The treatment associated radical surgery and radiotherapy. This rare kind of tumor is exceptionally diagnosed this way.

Adenocarcinoma, Papillary↗
PubMed2004

[Mola hydatidosa of the uterine tube].

A case of only rare localization of hydatidiform mole in fallopian tube is described. This localization is, recent clinical as ectopic pregnancy. In the last 25 years (1974-1999) was described only 30 cases of tubal localysation of hydatidiform mole.

Adult↗
PubMed2004

Primary fallopian tube carcinoma: a retrospective multicenter study.

PURPOSE: This retrospective multicenter study aimed to assess the survival and prognostic factors of primary fallopian tube carcinoma. METHODS: The medical records of 29 patients with fallopian tube carcinoma from two centers were reviewed for age, stage, surgical intervention, relapse and survival. RESULTS: The mean age of the patients was 56 years (range, 37-76). Six patients were in Stage I (20.7%), eight cases in Stage II (27.6%), nine cases in Stage III (31%) and two cases in Stage IV (6.9%). Data on stage was not available in four cases (13.8). Fifteen patients underwent lymph node evaluation. The median follow-up was 29 months (range, 3-122). The median survival was 95 months with a 5-year survival rate of 69.7%. The median progression-free survival was 76 months with a 5-year survival rate of 51.8%. CONCLUSION: Age, stage and lymphadenectomy were found to be significant prognostic factors on overall survival.

Adult↗
PubMed2004

Primary adenocarcinoma of the fallopian tube: a case report.

We report a case of a 75-year-old postmenopausal woman with primary fallopian tube carcinoma confined to the left fallopian tube in Stage IA-2, who is alive without evidence of disease three years after total abdominal hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, pelvic and paraaortic lymph node dissection were performed. Histopathological examination revealed a poorly differentiated (grade 3) papillary serous adenocarcinoma of the left fallopian tube. Adjuvant irradiation was given. Primary fallopian cancer should be suspected by clinicians even if the presenting symptoms are atypical and the primary treatment remains surgical resection followed by adjuvant chemotherapy or radiation. Appropriate therapy for each stage of the disease should be defined and new studies are needed to better depict the clinical course and prognostic factors.

Adenocarcinoma↗
PubMed2004

[Early stage fallopian tube carcinoma--diagnosis, staging and treatment].

Fallopian tube carcinoma is one of the rarest malignancies of the female genital tract. It is often diagnosed incidentally at an advanced stage. In recent years, an increase was observed in early stage fallopian tube carcinoma diagnosis. Such early diagnosis challenges the current FIGO staging system, as well as treatment recommendations, due to its limitations in precise discrimination between early stages. This is a case study of a 42 year-old woman, admitted for bilateral salpingo-oophorectomy due to bilateral ovarian cysts. Pathological examination incidentally revealed early staged fallopian tube carcinoma, which had invaded the lamina propria only, with no muscularis penetration. Due to the limited data regarding the efficacy of adjuvant chemotherapy at this early stage, only CA-125 levels follow-up was recommended.

Adult↗
PubMed1992

Postsalpingostomy intercornual bridging with hematosalpinx, chronic salpingitis and perisalpingeal endometriosis. A case report.

Two years after a left salpingo-oophorectomy for a tuboovarian mass from endometriosis and a right salpingostomy for hydrosalpinx, a 28-year-old, infertile woman underwent pelvic surgery for severe pain and progressive endometriosis. The closed, swollen tube arched over the posterior aspect of the uterus, bridging the two cornua; it was filled with blood and showed severe chronic salpingitis and widespread perisalpingeal endometriosis.

Adult↗
PubMed1992

Post-hysterectomy carcinoma of the fallopian tube mimicking a vesicovaginal fistula.

A 49-year-old woman presented with a profuse watery vaginal discharge 16 years after a vaginal hysterectomy. Pelvic examination revealed clear fluid leaking from the vaginal apex. Cytologic evaluation of the draining fluid was normal, as was a biopsy of the vaginal apex. A vesicovaginal fistula was suspected. Intravenous pyelogram and cystogram did not reveal communication of the urinary tract with the fistula. Injection of radiopaque dye through the fistula tract demonstrated a 5-7-cm enclosed cystic space with a 4-cm pedunculated mass within the cyst lumen. Exploratory surgery revealed fallopian tube carcinoma involving the right tube. The tumor mass was completely excised, and there was no evidence of spread beyond the encapsulated cystic fallopian tube. The woman was treated with six cycles of cisplatin combination chemotherapy, and after 5 years remains free of disease.

Adenocarcinoma↗
PubMed1992

[Primary adenocarcinoma of the fallopian tube. Retrospective study of 16 cases. Prognostic factors].

The authors report the result of a study carried out on 16 cases of tubal adenocarcinoma treated between the years 1975 and 1988. This is a rare gynaecological cancer with a poor prognosis. The mean age of the patients was 57 years, 64.5% of them were menopausal. 25% had had a history of sterility. 29% were nulliparous and 37.5% had previous salpingitis. In 44% of cases the principal clinical signs were a watery discharge and a blood stained discharge. Pelvic pain occurred in 37% of the cases and CT scan showed a pelvic mass in 50% of cases. Hysterosalpingography and ultrasound were two complimentary investigations. The relatively early stage at which first signs of the condition were noted, show the stages of the disease: stage I 68.7%, stage II 25%, stage III 6.2%, stage IV 0%. Surgery above all was the basis of treatment carried out in all cases, and supplemented in 15 out of the 16 cases by added treatment (radiotherapy, chemotherapy of hormone therapy). As far as histology was concerned, well or moderately well differentiated forms were found to predominate (there were 37.5% grade I and 37.5% grade II) against only 26% for grade III. More than half of the tube wall was infiltrated in 50% of cases. The actuarial survival rate after 5 years was 33%. The authors examine the principal factors responsible for the prognosis, the tissue, the early diagnosis and the possibility of removing the tumour completely at the first operation as well as the histological grading and above all the degree of depth of infiltration of the wall of the tube.

Adenocarcinoma↗